Stefan Heck studied chemistry at Darmstadt Technical University and received his Ph.D. from TU Munich.
After earning his degree, he was employed at different companies in Switzerland (e.g. Siegfried AG, Carbogen Amcis, Fareva) where he served several functions related to pharmaceutical production, project management and business development.
Today Stefan is working as a business development manager at Intertek (Schweiz) AG and takes responsibility for all Intertek clients in the DACH region.
A variety of process materials and reactive compounds are involved in the synthesis of pharmaceutical products. As a consequence, residues of such compounds and related degradation products can later be found as drug impurities in API and final formulation Some of those impurities are known to be mutagenic with the potential to cause adverse effects on the human body even when only present at trace level concentrations.
The detection, quantification and evaluation of such impurities is important but can be very challenging since matrix effects often discriminate these compounds. In many cases the route of synthesis allows to predict potential impurities. However, in other cases unexpected genotoxic compounds may be an issue since predictability is limited due to complexity of processes and formulations.
In our presentation we highlight the analytical challenges and propose possible solutions:
Case studies and examplesView Details